P. Papanastasiou

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

David M. Reid, Jean‐Pierre Devogelaer, Kenneth G. Saag et al. · The Lancet · 2009 · 529 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +12

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

Felicia Cosman, Erik Fink Eriksen, Chris Recknor et al. · Journal of Bone and Mineral Research · 2010 · 359 citations

Medicine, Endocrinology, Pharmacotherapy +10

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Steven Boonen, Jean‐Yves Reginster, Jean‐Marc Kaufman et al. · New England Journal of Medicine · 2012 · 359 citations · Full text

Medicine, Pharmacotherapy, Bone Metabolism +13

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis

Stephen Jarrett, Philip G. Conaghan, Victor S. Sloan et al. · Arthritis & Rheumatism · 2006 · 153 citations

Medicine, Clinical Sciences, Pharmacotherapy +17

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

Christine Bodemer, Andrzej Kaszuba, Külli Kingo et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 94 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13